T 0201/18 of 27.07.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T020118.20200727
- Date of decision
- 27 July 2020
- Case number
- T 0201/18
- Petition for review of
- -
- Application number
- 09704256.8
- IPC class
- A61K 31/506A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHOD OF OPTIMIZING THE TREATMENT OF PROLIFERATIVE DISEASES MEDIATED BY THE TYROSINE KINASE RECEPTOR KIT WITH IMATINIB
- Applicant name
- Novartis AG
- Opponent name
- Generics [UK] Limited (trading as Mylan)
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(2) (2007)
- Keywords
- Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked - Catchword
- -
- Cited cases
- T 0073/84
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.